ArticleWorld journal of gastrointestinal oncology2025
Associations between blood metabolite levels and gastrointestinal cancer risk: A preliminary untargeted metabolomics study.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the barrier: Engineering the tumor-immune-soil nexus-a mechanistic blueprint for integrating Traditional Chinese Medicine with immunotherapy in metastatic colorectal cancer.Medical oncology (Northwood, London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal cancers are among the most commonly diagnosed cancers globally. Traditional Chinese medicine (TCM) offers distinct advantages in preventing and treating these cancers.
aimTo investigate the metabolic basis of a common TCM syndrome in gastrointestinal cancers, exploring underlying metabolic mechanisms and identifying potential biomarkers.
methodsThirty healthy controls (normal group), 30 patients with gastric cancer (GC), and 30 patients with colorectal cancer (CRC) were enrolled in 2023. Plasma metabolic profiles were detected using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry, and pathway enrichment analysis was conducted using the Kyoto Encyclopedia of Genes and Genomes.
resultsMetabolic profiling revealed distinct alterations in gastrointestinal cancers. CRC samples exhibited 455 differentially expressed metabolites (234 upregulated and 221 downregulated). Similarly, GC samples exhibited 459 differentially expressed metabolites (251 upregulated and 208 downregulated). Additionally, 352 shared metabolites were identified among gastrointestinal cancers. Enrichment analysis highlighted the involvement of these shared metabolites in 10 metabolic pathways.
conclusionTo some extent, this study revealed the metabolomic characteristics of spleen deficiency and blood stasis toxin (PXYD) syndrome in gastrointestinal cancers. It provides the rationale for the "same treatment for different diseases" approach in PXYD syndrome of gastrointestinal cancers, and for identifying potential metabolomics-based biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.